

NOVARTIS AG

ISIN: CH0012005267 WKN: 1200526 Asset Class: **Stock**

| | |
|--|---|
| Company | 2022/09/23 18:21:38 |
|  | Price 74.36 CHF |
| | Difference  -0.92% (-0.69) |



| |
|--|
| Contact Details |
| NOVARTIS AG Tel: 41-61-324-11-11 |
| -- Fax: 41-61-324-80-01 |
| Lichtstrasse 35 Web: http://www.novartis.com |
| 4056 Basel E-mail: - |

Company Profile

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Financial figures, Fiscal year: from 01.01. to 31.12.

| Financial figures | 2021 | | 2020 | | 2019 | |
|---------------------------------------|-----------------|------------------------|-----------------|------------------------|-----------------|------------------------|
| | Assets | Liabilities and equity | Assets | Liabilities and equity | Assets | Liabilities and equity |
| Current assets | 41,655,955,000 | | 26,229,448,000 | | 28,570,198,000 | |
| Common stock capital | | 820,946,000 | | 807,046,000 | | 906,375,000 |
| Fixed assets | 82,154,750,000 | | 90,619,018,000 | | 86,095,030,000 | |
| Equity capital of a company | | 61,796,015,000 | | 50,089,910,000 | | 53,792,810,000 |
| Cash and cash equivalents | 11,304,638,000 | | 8,537,189,000 | | 10,760,305,000 | |
| Accrued liabilities | | 4,279,671,000 | | 4,897,966,000 | | 5,247,488,000 |
| Other assets | - | | - | | - | |
| Current liabilities | | 27,524,019,000 | | 29,222,503,000 | | 27,369,444,000 |
| Prepayments and accrued income | - | | - | | - | |
| Non-current liabilities | | 34,490,672,000 | | 37,536,052,000 | | 33,502,973,000 |
| Different income | | - | | - | | - |
| Other liabilities | | 1,343,946,000 | | 1,231,342,000 | | 1,174,608,000 |
| Total assets | 123,810,706,000 | 123,810,706,000 | 116,848,466,000 | 116,848,466,000 | 114,665,228,000 | 114,665,228,000 |

Balance notes

| | 2021 | 2020 | 2019 |
|----------------------------|---------|---------|---------|
| Accounting standard | IFRS | IFRS | IFRS |
| Employees | 104,323 | 105,794 | 103,914 |
| Equity ratio | 50.03% | 42.92% | 46.98% |
| Debt-equity ratio | 99.86% | 133.00% | 112.87% |

Others

| | 2021 | 2020 | 2019 |
|-------------------------|--------|--------|--------|
| Tax Expense Rate | 19.62% | 19.63% | 21.65% |

Income statement

| | 2021 | 2020 | 2019 |
|--|----------------|----------------|----------------|
| Turnover | 47,199,917,000 | 45,672,013,000 | 47,202,693,000 |
| Net income | 21,961,593,000 | 7,576,491,000 | 7,097,596,000 |
| EBIT | 11,180,962,539 | 9,901,331,964 | 9,339,612,042 |
| Operating income before taxes | 9,872,248,000 | 8,639,940,000 | 8,229,514,000 |
| Cash Flow | 13,778,909,000 | 12,812,079,000 | 13,540,289,000 |
| Net interest income | -766,155,000 | -780,926,000 | -656,890,000 |
| Research and development expenses | 8,722,101,000 | 8,428,752,000 | 9,343,545,000 |
| Income taxes | 1,937,330,000 | 1,696,075,000 | 1,781,852,000 |
| Result from investments in subsidiaries, associates and other | 14,023,932,000 | 631,687,000 | 654,902,000 |
| Revenues per employee | 475,515 | 453,724 | 477,414 |

Board of Directors

| | |
|---------------------|--------------------------------------|
| Andreas von Planta | Member of the administrative board |
| Charles Sawyers | Member of the administrative board |
| Nancy Andrews | Member of the administrative board |
| Simon Moroney | Member of the administrative board |
| Ana de Pro Gonzalo | Member of the administrative board |
| Bridgette Heller | Member of the administrative board |
| Daniel Hochstrasser | Member of the administrative board |
| Eric Boutin | Member of the administrative board |
| Frans van Houten | Member of the administrative board |
| Mary Doherty | Member of the administrative board |
| Patrice Bula | Member of the administrative board |
| Ton Büchner | Member of the administrative board |
| William Winters | Member of the administrative board |
| Hans Jörg Reinhardt | Chairman of the administrative board |

Members of Management Board

| | |
|-------------------------|-------------------------------|
| Vasant Narasimhan, M.D. | Chairman of Managing Board |
| James E. Bradner | Member of Executive Committee |
| Klaus Moosmayer | Member of Executive Committee |
| Steffen Lang | Member of Executive Committee |
| Susanne Schaffert | Member of Executive Committee |
| Harry Kirsch | Member of Executive Committee |
| John Tsai, M.D. | Member of Executive Committee |
| Karen L. Hale | Member of Executive Committee |
| Marie-France Tschudin | Member of Executive Committee |
| Richard Saynor | Member of Executive Committee |
| Rob Kowalski | Member of Executive Committee |
| Robert Weltevreden | Member of Executive Committee |